Literature DB >> 28556499

The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule.

Mary C Brucker, Tekoa L King.   

Abstract

As of 2015, the US Food and Drug Administration (FDA) discontinued the pregnancy risk categories (ABCDX) that had been used to denote the putative safety of drugs for use among pregnant women. The ABCDX system has been replaced by the FDA Pregnancy and Lactation Labeling Rule (PLLR) that requires narrative text to describe risk information, clinical considerations, and background data for the drug. The new rule includes 3 overarching categories: 1) pregnancy, which includes labor and birth; 2) lactation; and 3) females and males of reproductive potential. This article reviews the key components of the PLLR and clinical implications, and provides resources for clinicians who prescribe drugs for women of reproductive age.
© 2017 by the American College of Nurse-Midwives.

Entities:  

Keywords:  Food and Drug Administration; drug safety; drugs; lactation; pregnancy; teratogens

Mesh:

Substances:

Year:  2017        PMID: 28556499     DOI: 10.1111/jmwh.12611

Source DB:  PubMed          Journal:  J Midwifery Womens Health        ISSN: 1526-9523            Impact factor:   2.388


  8 in total

Review 1.  Small Molecules and Antibodies for Zika Therapy.

Authors:  Xuping Xie; Jing Zou; Chao Shan; Pei-Yong Shi
Journal:  J Infect Dis       Date:  2017-12-16       Impact factor: 5.226

2.  Brain-wide genetic mapping identifies the indusium griseum as a prenatal target of pharmacologically unrelated psychostimulants.

Authors:  Janos Fuzik; Sabah Rehman; Fatima Girach; Andras G Miklosi; Solomiia Korchynska; Gloria Arque; Roman A Romanov; János Hanics; Ludwig Wagner; Konstantinos Meletis; Yuchio Yanagawa; Gabor G Kovacs; Alán Alpár; Tomas G M Hökfelt; Tibor Harkany
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-03       Impact factor: 11.205

3.  A case report of pulmonary arterial hypertension in pregnancy and complications of anticoagulation therapy.

Authors:  Yangfang Xiang; Jun Li; Yinxiang Sun
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

4.  COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding.

Authors:  Marcelo Borges Cavalcante; Candice Torres de Melo Bezerra Cavalcante; Ana Catherine Sampaio Braga; Dennyse Araújo Andrade; Mariana Albuquerque Montenegro; Paula Andrade Neiva Santos; Paula Vitória Pereira Motoyama; Marcelo Gondim Rocha; Luciana Azôr Dib; Edward Araujo Júnior
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-01-19       Impact factor: 2.915

5.  Perceived risks of over-the-counter medication use among pregnant Saudi mothers: A cross-sectional study.

Authors:  Ashwaq Ayidh M Alosaimi; Sahar M Zamzam; Daniel Joseph E Berdida; Hazel N Villagracia
Journal:  J Taibah Univ Med Sci       Date:  2022-03-20

6.  Parkinson's Disease in Pregnancy: A Case Report and Review of the Literature.

Authors:  Sara Olivola; Serena Xodo; Enrica Olivola; Fabiana Cecchini; Ambrogio Pietro Londero; Lorenza Driul
Journal:  Front Neurol       Date:  2020-02-19       Impact factor: 4.003

7.  Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis.

Authors:  Patricia Nicolas; Marta F Maia; Quique Bassat; Kevin C Kobylinski; Wuelton Monteiro; N Regina Rabinovich; Clara Menéndez; Azucena Bardají; Carlos Chaccour
Journal:  Lancet Glob Health       Date:  2020-01       Impact factor: 38.927

8.  Protocol of a prospective and multicentre China Teratology Birth Cohort (CTBC): association of maternal drug exposure during pregnancy with adverse pregnancy outcomes.

Authors:  Jun Zhu; Xiaohong Li; Yangwen Zhou; Jing Tao; Ke Wang; Kui Deng; Yanping Wang; Jianxin Zhao; Chunyi Chen; Tingxuan Wu; Jiayuan Zhou
Journal:  BMC Pregnancy Childbirth       Date:  2021-09-01       Impact factor: 3.007

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.